Adenosine A 3 receptor (A 3 R), is a promising drug target against cancer cell proliferation. Currently there is no experimentally determined structure of A 3 R. Here, we have investigate a computational model, previously applied successfully for agonists binding to A 3 R, using molecular dynamic (MD) simulations, Molecular Mechanics-Poisson Boltzmann Surface Area (MM-PBSA) and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Extensive computations were performed to explore the binding profile of O4-{[3-(2,6-dichlorophenyl)-5-methylisoxazol-4yl]carbonyl}-2-methyl-1,3-thiazole-4-carbohydroximamide (K18) to A 3 R. K18 is a new specific and competitive antagonist at the orthosteric binding site of A 3 R, discovered using virtual screening and characterized pharmacologically in our previous studies. The most plausible binding conformation for the dichlorophenyl group of K18 inside the A 3 R is oriented towards trans-membrane helices (TM) 5 and 6, according to the MM-PBSA and MM-GBSA binding free energy calculations, and by the previous results obtained by mutating residues of TM5, TM6 to alanine which reduce antagonist potency. The results from 14 site-directed mutagenesis experiments were interpreted using MD simulations and MM-GBSA calculations which show that the relative binding free energies of the mutant A 3 R -K18 complexes compare to the WT A 3 R are in agreement with the effect of the mutations, i.e. the reduction, maintenance or increase of antagonist potency. We show that when the residues V169 5.30 , M177 5.38 , I249 6.54 involved in direct interactions with K18 are mutated to alanine, the mutant A 3 R -K18 complexes reduce potency, increase the RMSD value of K18 inside the binding area and the MM-GBSA binding free energy compared to the WT A 3 R complex. Our computational model shows that other mutant A 3 R complexes with K18, including directly interacting residues, i.e. F168 5.29 A, L246 6.51 A, N250 6.55 A complexes with K18 are not stable. In these complexes of A 3 R mutated in directly interacting residues one or more of the interactions between K18 and these residues are lost. In agreement with the experiments, the computations show that, M174 5.35 a residue which does not make direct interactions with K18 is critical for K18 binding. A striking results is that the mutation of residue V169 5.30 to glutamic acid maintained antagonistic potency. This effect is in agreement with the binding free energy calculations and it is suggested that is due to K18 re-orientation but also to the plasticity of A 3 R binding area. The mutation of direct interacting L90 3.32 in the low region and the non-directly interacting L264 7.35 to alanine in the middle region increases the antagonistic potency, suggesting that chemical modifications of K18 can be applied to augment antagonistic potency. The calculated binding energies ΔG eff values of K18 against mutant A 3 Rs displayed very good correlation with experimental potencies (pA 2 values). These results further approve the computational model for the description of K18 binding with critical residues of the orthosteric binding area which can have implications for the design of more effective antagonists based on the structure of K18. computational time granted from the Greek Research & Technology Network (GRNET) in the National HPC facility -ARIS -under project IDs pr002021 and pr001004).
Introduction
Adenosine is a naturally occurring purine nucleoside and an endogenous agonist of adenosine receptors. 1 The adenosine receptors are G protein-coupled receptors (GPCRs) comprising four subtypes; A 1 , A 2A , A 2B and A 3 . In particular, A 2A and A 2B subtypes act synergistically with the G s proteins resulting in the stimulation of the adenylyl cyclase, and therefore, the increase of 3′,5′-cyclic adenosine monophosphate (cAMP) levels. In contrast, A 1 and A 3 subtypes inhibit the adenylyl cyclase and decrease cAMP levels within a cell by coupling to G i family of G proteins. Recent studies have shown that A 3 R is overexpressed in various tumor cells. 2 This makes A 3 R and its signaling pathway a promising drug target against cancer and for a number of other conditions like inflammatory diseases, including asthma and rheumatoid arthritis, glaucoma, chronic obstructive pulmonary disease and ischemic injury. 1 Experimentally resolved structures of A 2A R showing the binding mode of agonists, like adenosine and 5′-(N-ethylcarboxamido)adenosine (NECA), [3] [4] [5] as well as of several antagonists i.e., CGS-21689, 6 UK-432097, 7 ZM241385, [8] [9] [10] PSB36, caffeine and theophylline [11] [12] [13] [14] and one bound to an engineered G protein 4 have been determined since 2008. 5 Experimental structures showed also the binding of A 1 R with the antagonists DU172 15 and PSB36 16, 17, 18 and the adenosine-bound A 1 R-G i complex. 19 These experimental A 2A R and A 1 R structures provided excellent templates for structure-based drug design. 20, 21 In contrast, the experimental structure for A 3 R has, to date, not been resolved. It has been observed that differences in the residues of the upper region of the orthosteric binding area define the selectivity of ligands against particular AR subtypes. 22 The A 3 R accommodates ligands having groups of increased lipophilicity fitted in the area close to V169 5. 30 . This lipophilic area in-between EL2, TM5 and TM6 is unique for A 3 R and has a characteristic residue V169 5.30 , while A 1 R and A 2A R and A 2B R have a glutamic acid residue in the same position. As a first approach, we use a homology model of A 3 R, built based on A 2A R in order to study the orthosteric binding area related to the function of this receptor. In our previous study, a fair description of the binding profile of the selective agonist IB-MECA and the nonselective NECA to A 3 R was achieved through intensive computational work using the A 3 R model, the application of MM-GBSA calculations and extensive mutagenesis. 23 Scheme 1. K18 and K11, K10, K32 which were measured experimentally in ref 24 . in parentheses are included the binding affinities from radiolabelled binding experiments and the antagonist potencies in micromolar concentrations; n.a. means an inactive compound in functional assays.
We have explored an in silico screening of 14,400 compounds of Maybridge HitFinder library against the X-ray structure of A 2A R complex bound with the selective antagonist ZM241385 using a combination of ligand-and structure-based approaches. 25 Of particular interest for further development was the class of carbohydroximamide derivatives of which K18 was identified as a potent and selective A 3 R antagonist in a previous study (Scheme 1). 24 In that research, 24 we studied experimentally the effect of mutations L90 3.32 , V169 5.30 , M174 5.35 , M177 5.38 , I249 6.54 , I253 6.58 , L264 7.35 , W185 5.46 /V169 5.30 to alanine within the orthosteric binding area of A 3 R to the antagonistic potency of K18. 24 The I253 6.58 E, V169 5.30 E mutants were also explored. Furthermore, in another study we performed mutagenesis and intensive computational work to investigate the binding profile of the selective agonist 1-deoxy-1- [6-[[(3iodophenyl )methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamide (IB-MECA) and the nonselective NECA to A 3 R. 23 A fair description was accomplished using homology models for the mutant A 3 Rs and the amber99sb force field and through the application of MM-GBSA binding free energy calculations.
As a continuation of these studies, we aimed to investigate, in detail, the binding profile and binding area of the antagonist K18. K17 was also found to be competitive antagonist in the previous study, although less potent compared to K18, having less one chloride atom connected with the phenyl group.
Commercial compound libraries have not available dichlorophenyl analogues of K18, and seeking to study the effect of modifying additional fragments of the active chemical probe, we purchased compounds K11, K10 and K32 analogues of K17 (Scheme 1). K11, K10 and K32 have a pyridinyl substituent, instead of 1,3-thiazolyl, which is linked with carbonyloxycarboximidamide linker through C2, C3 and C4 carbons, respectively. K32, K10 show potent antagonistic potency while K11 is inactive.
We applied MD simulations and MM-PBSA, MM-GBSA calculations 26, 27 in the complexes of K18, K32, K10, K11 with WT A 3 R to study the interactions of the ligands with orthosteric binding area and the residues involved in binding with higher interaction frequency. The stability of complexes between K18 and 14 A 3 R mutated receptors is investigated computationally through MD simulations and MM-GBSA calculations and compare with the experimental site-directed mutagenesis results. 21 
Methods

Computational Biochemistry
Preparation of Receptor Structures -Molecular docking calculations
Receptor structures. The complex of the inactive form of the WT A 2A R (PDB ID 3EML) 11 with ZM241385 was superimposed to the model of inactive WT A 3 R (N12 1.32 -H304 7.75 ) derived from Adenosiland web-service 28 that was built using the crystal structure of PDB ID 3EML as template 28 (numbers in parentheses refer to the Ballesteros-Weinstein numbering 29 ). The inactive protein conformation of A 2A R was removed resulting in the ZM241385-inactive WT A 3 R model. In the A 3 R WT model, the side chain of V169 5.30 was rotated as suggested 30 to increase the free space for the accommodation of agonists with bulky substitutions. 31 The ZM241385-inactive A 2A R protein complex (PDB ID 3EML) 11 was superimposed to NECA-active A 2A R protein complex with PDB ID 2YDV. 3 Then the NECA and inactive protein conformation were removed resulting in ZM241385-active A 2A R complex model. As a next step, the ARs were optimized using the Protein Preparation Wizard implementation in Schrodinger suite. 32 In this process, the bond orders and disulfide bonds were assigned, and missing hydrogen atoms were added. Additionally, N-and C-termini of the protein model were capped by acetyl and N-methyl-amino groups, respectively. The systems were subjected in an allatom minimization using the OPLS2005 force field 33 with heavy atom RMSD values constrained to 0.30
Å.
After MD simulation of the K18-A 3 R complex, the equilibrated structure was used for the preparation of the mutant receptor models of WT A 3 R complex by changing the studied residues to alanine, through the "Build" tool of Maestro. The 14 mutant A 3 Rs mentioned in the last paragraph of the introduction section in complex with K18 were subjected in minimization using the previously used protocol.
Docking calculations. K18 was prepared for docking calculations using Maestro. 34 The ZM241385inactive WT A 3 R model was used as a template for docking of K18 in the apo A 3 R. For this purpose, ZM241385, utilized as a reference ligand, and apo protein WT A 3 R were saved separately. Ligand binding site was defined within 10 Å of ZM241385 coordinates. Molecular docking calculations of the energy minimized form of K18 were performed using GoldScore 35 scoring function in GOLD 5.2 software, [35] [36] [37] applying 30 genetic algorithm runs. The "allow early termination" option, which terminates ligand searching if the top three solutions have an RMSD difference less than 1.5 Å was inactivated, and the "Generate Diverse Solutions" option, which sets smallest inter-cluster RMSD to 1.5 Å, was activated. All other parameters were set to their default values. The resulting highest-scoring pose had the dichlorophenyl group with an orientation towards TM5, TM6 and the second one had the dichlorophenyl group with an orientation towards TM1, TM2. From now on we will refer to these conformations as "up TM5,TM6" and "up TM1,TM2". For the investigation of the most likely conformation of K18 inside the WT A 3 R we kept the 6 th scored docking pose with the isoxazoledichlorophenyl instead of the thiazole ring oriented deep in the A 3 R. This will be referred as "down" conformation A set of 75 structures were selected from PubMed based on their best similarity with K18 using TanimotoCombo metric, which is the sum of the ShapeTanimoto (metric of shape) and ColorTanimoto (metric of functional group) scores, 38 and were prepared for docking calculations using Maestro. 34 The energy minimized form of these 75 structures was docked in the inactive form of WT A 3 R using Glide XP; the docking poses produced were subjected to Induced Fit Docking (IFD). 39 The commercially available compounds K40-K43 which contain both 3-(dichlorophenyl)-5-methylisoxazole and thiazole were selected, purchased and biologically tested. The 14 mutant A 3 Rs in complex with the best docking pose of K18 in the WT A 3 R were used for molecular docking calculations using the same procedure described above.
MD simulations between ligands and A 3 R MD simulations of K18, K40-K44 with WT A 3 R. Complexes of the previously mentioned K18
conformations i.e., "up TM5,TM6", "up TM1,TM2" and "down", molecules K40-K44 with the WT A 3 R model were inserted in a pre-equilibrated hydrated POPE membrane bilayer. The MD simulations were performed with Desmond software and the OPLS2005. The orthorhombic periodic box boundaries were set 15 Å away from the protein atoms. The system contained 150 lipids, 15,000 water molecules corresponding to the TIP3P water model and salt concentration 0.15M NaCl and was built using the System Builder utility of Desmond. 40, 41, 42 The total number of atoms of each complex was approximately ~70,000. Desmond Viparr tool was used to assign amber99sb force field parameters 43, 44 to protein and lipid, and GAFF 45 was used for the parameters of the ligand. Initial ligand parameters were constructed with the antechamber module of Amber14. 46 MD simulations were performed at 310 K in order to ensure that the membrane state is above the main phase transition temperature of 298 K for POPE bilayers. 47 The MD simulations were also performed at 310 K using a buffered orthorhombic system in 10 Å distance from the solute atoms with periodic boundary conditions for all the complexes using AMBER14 software. Each complex-bilayer system was processed by the LEaP module in AmberTools14 under the AMBER14 software package. 48 Amberff14SB force field parameters 49 were applied to the protein, lipid14 to the lipids, 50 Generalized Amber Force Field (GAFF) to the ligands 45 and TIP3P 51 to the water molecules for the calculation of bonded, van der Waals and electrostatic interactions. Atomic charges were computed according to the RESP procedure 52 using Gaussian03 53 and antechamber module of AmberTools14. 48 The MD simulations protocols are described in the Supporting Information.
In the production phase, the relaxed systems were simulated in the NPT ensemble conditions for 100 ns.
Within this simulation time, the total energy and the RMSD of the protein's backbone Cα atoms reached a plateau, therefore the systems were considered equilibrated and suitable for statistical analysis.
MD simulations of K18 with mutant A 3 Rs.
The stability of the complexes between K18 and the 14 mutant A 3 Rs was investigated using MD simulations for 100 ns with Schrodinger Desmond Maestro v11.1 and the amber99sb force field using the same protocol described above. Within this simulation time, the total energy and RMSD of the of the protein backbone Cα atoms reached a plateau, and the systems were considered equilibrated and suitable for statistical analysis.
Analysis of MD simulations trajectories. The visualization of produced trajectories was performed using the GUI of Maestro and the protein-ligand interaction analysis was done with the Simulation
Interaction Diagram (SID) tool, available with Schrodinger Desmond Maestro v. 11.1. For hydrogen bond interactions, a distance of 2.5 Å between donor and acceptor heavy atoms, and an angle ≥120 o between donor-hydrogen-acceptor atoms and ≥ 90 o between hydrogen-acceptor-bonded atom were considered.
Non-specific hydrophobic contacts were identified when the side chain of a hydrophobic residue fell within 3.6 Å from a ligand's aromatic or aliphatic carbon, while π-π interactions were characterized by stacking of two aromatic groups face-to-face or face-to-edge. Water-mediated interactions were characterized by a distance of 2.7 Å between donor and acceptor atoms, as well as an angle ≥ 110 o between donor-hydrogen-acceptor atoms and ≥ 80 o between hydrogen-acceptor-bonded atom. The visualization of produced trajectories and structures was performed using the programs Chimera 54 and VMD. 55 All the MD simulations were run on GTX 1060 GPUs in lab workstations or on the ARIS Supercomputer.
MM-PBSA and MM-GBSA calculations
The effective binding free energies (ΔG eff ) of the complexes between the three docking poses of K18, K40-K43 and A 3 R complexes were computed considering the gas phase energy and solvation free energy contributions to binding 56 using the 1-trajectory MM-PBSA, MM-GBSA approach. 57 For this, structural ensembles for each complex were extracted every 50 ps from the last 50 ns of the production simulations.
Prior to the calculations all water molecules, ions, and lipids were removed, and the structures were positioned such that the geometric center of each complex was located at the coordinate origin. For MM-PBSA calculations, molecular mechanics energies and the non-polar contribution to the solvation free energy were computed with the mmpbsa.pl module 58 of Amber14. 48 For MM-GBSA calculations the relevant module in Schrodinger Suite was used, i.e. the thermal_mmgbsa.pyscript that takes individual trajectory snapshots and calculates ΔG eff and its energetic contributions (see Supporting Information).
Results and Discussion
Validation of the force field for the MD simulations
Since there is no experimental structure for A 3 R, we chose A 2A R to test a computational model that can be accurate for our calculations with antagonists. In a previous paper we tested how different force fields describe the interactions between agonist NECA and the orthosteric binding area of A 2A R in the experimental structure. We found that amber99sb can accurately describe the interactions as well as the conformation of helical TM regions. 23 Here, we test the performance of amber99sb force field for an antagonist-A 2A complex using the experimental structures of A 2A R in the active 3 and the inactive state. 59, 10 We tested if amber99sb can produce conformational changes that ZM241385 binding can effect to the active state of A 2A R towards the complex of ZM241385 with the inactive state of A 2A R. 59 After 300 ns of simulation the ZM241385-active A 2A R complex adopted an inactive-like conformation of A 2A R having an RMSD of ca 2 Å compared to the experimental structure PDB ID 3EML. 11 The conformational changes observed are: (a) decrease in the distance between TM3-TM6; the distance between R102 3.50 and A232 6.34 Cα carbons changed from 11 to 7.5 Å (Figure 1 respectively; this change in the dihedrals caused W243 6.48 indole ring placement almost horizontal to TM3. (d) formation of the ionic lock between R102 3.50 and E228 6.30 . These measures showed that amber99sb force field is sensitive in describing A 2A R receptor conformational changes and can be applied for the simulations of antagonists like K18 in complex with A 3 R. In addition, our previous study suggested that amber99sb is suitable for the simulations of agonist nucleosides in complex with adenosine receptors. 23 
MD simulations of K18 and congeneric compounds in complex with WT A 3 R
The MD simulation with the "up TM5, TM6" conformation (see methods section) as starting structure converged in a stable conformation with an RMSD of less than 2 Å compared to the starting structure. 24 Interestingly, the MD simulations revealed that starting from conformation "up TM1, TM2", K18 rotated phenyl-oxazolyl bond but also N-O bond resulting in a conformation with a dichlorophenyl orientation also towards TM5, TM6 conformation ( Figure 2A ) with a relative binding free energy ΔΔG eff = + 3.8 compared to "up TM5, TM6" starting structure conformation ( Figure 2B ) according to both MM-PBSA and MM-GBSA calculations.
The MD simulations of K18 in complex with WT human A 3 R showed that the most frequent (>20% of the MD trajectory) contacts involved V72 2.23 , L90 3.32 , F168 5.29 , V169 5.30 , M177 5.38 , L246 6.51 , I249 6.54 , N250 6.55 as previously found, 24 and less than 15% was recorded for van der Waals with V65 2.16 , I186 5.47 and L264 7.35 . Hydrophobic contacts were measured in the MD simulations and are showed in the interaction fraction plot ( Figure 2D ) when the side chain of a hydrophobic residue fell within 3.6 Å from the ligand. In particular, as shown in the binding conformation the phenyl group of the 3-phenylisoxazole interacts through attractive van der Waals forces with V169 5.30 and I249 6.54 and the isoxazole adopts an aromatic π-π stacking interaction with the phenyl group of F168 5.29 . Nitrogen and oxygen atoms of isoxazole can be hydrogen bonded to NH groups of F168 5.29 or V169 5.30 . The thiazolyl group can be hydrogen bonded to N250 6.55 and have van der Waals interactions with L90 3.32 , M177 5.38 , L246 6.51 and V72 2.23 . The "down" conformation of K18 was unstable, the ligand lost binding interactions and shifted away the binding area ( Figure 2C ). MM-PBSA calculations 57,56 further supported the "up TM5, TM6" conformation of K18 since, as described in ref. 24 the relative ΔG eff values between K18 and two congeners having one or no chlorine atoms, i.e. compounds K17 and K5 (Scheme 1), were in agreement with experimental binding affinities and activities. 24 K17 having one chlorine atom in the phenyl ring compared to K18 had antagonistic potency and similar binding profile to K18 (Scheme 1, Figure S1 ). 24 In contrast K5 with no chlorine atoms lack of antagonistic potency. In contrast the "up TM1, TM2" conformation did not account for the relative experimental binding free energy differences. inside WT A 3 R and average structure from 100 MD simulations (carbon atoms in yellow). The side chains of residues involved in ligand binding, separated by 3.6 Å from the ligand and having interaction frequencies ≥ 0.2 are displayed as gray sticks. Protein structure is displayed in grey ribbons. In pink residues which were mutated to alanine but are more than 4 Å apart from the ligand are displayed. A congeneric series to K17 are compounds K11, K10 and K32 having a pyridinyl substituent, instead of 1,3-thiazolyl, which is linked with carbonyloxycarboximidamide linker through C2, C3 and C4 carbons, respectively. K11, K10 and K32 have more similar structure to K17 compared to K18, having one chlorine atom in the phenyl ring rather than two chlorine atoms in K18. Since, we found no commercially available the pyridine analogues to K18 we have explored K17 derivatives aiming at improving potency of K18 by investigating structure-activity relationships of various parts of the molecule.
The MD simulations suggested that compound K32 can form an additional hydrogen bond interaction with N250 6.55 through 2-pyridinyl nitrogen ( Figure 3C ) and also has a 2-fold higher affinity than K10, K11. K10 also formed a hydrogen bond between pyridinyl nitrogen with S247 6.52 ( Figure 3B ). The binding free energy values derived from MM-PBSA calculations (ΔG eff ) fairly agree with this ranking (Table 1) supporting the proposed binding mode of K18. However, the biological assays showed that K32 and K10 are competitive antagonists like K17, but K11 did not have any effect on signaling below the tested concentration of 10 µM, suggested that antagonistic potency cannot be correlated directly with affinity. 1 Van der Waals energy of binding calculated using molecular mechanics 2 Electrostatic energy of binding calculated using molecular mechanics 3 Difference in solvation energy between the complex, the protein and the ligand, i.e. G complex, solv -( G protein, solv + G ligand, solv ) 4 Effective binding free energy calculated as ΔG eff = ΔE ΜΜ + ΔG sol ; in Table 1 , ΔE ΜΜ = Ε vdW + E EL (see Materials and Methods Section) 5 pK B obtained through Schild analysis in A 3 R stably expressing Flp-In CHO cells. 24 6 K i values (μΜ) previously published for K5, K17 and K18 60 through radio-ligand binding assays. Figure S2 ).
Simulations of K18 in complex with mutant versions of A 3 R
MM-GBSA binding free energy calculations. In order to investigate computationally the stability and the interactions for each mutant A 3 R-agonist complex with K18 their complexes in a hydrated POPE bilayer were subjected to MD simulations for 150 ns and MM-GBSA calculations were performed in the resulting trajectories. The previously experimentally determined pA2 values 24 were included in Table 2; it is recalled that an increase in the pA 2 value of K18 for a particular mutant A 3 R (when compared to WT A 3 R) shows that the antagonist was more active and a decrease indicated a reduced potency. The pA2 values and the calculated effective binding free energies (ΔG eff ) 57, 56 (Table S1 , Figure S3 ) showed significant correlation for K18 r = -0.82 (95% confidence interval, -0.94 to -0.68 (n=12), p < 0.01) ( Figure 4 ). In a previous study, the binding free energy calculations of agonists in complex with A 3 Rs using the MM-GBSA method showed also fair correlation. 23 We observed that mutants V169 5.30 A, M174 5. 35 A, M177 5.38 A, W185 5.46 A/V169 5.30 A, which led to reduction or loss of potency of K18, display relative binding free energy values (ΔΔG eff = ΔG eff,mut -ΔG eff , WT ) for the studied agonist greater than +10 kcal mol -1 compared to the WT receptor (Table 2, Figure S3 ). Similarly, the calculations also show that the complexes of K18 with mutant F168 5.29 A, L246 6.51 A, N250 6.55 A A 3 Rs are not favored ( Table 2 ). The effect of mutant F168 5.29 A, L246 6.51 A and N250 6.55 A A 3 Rs can not be explored experimentally by mutagenesis. These receptors produce no detecting response to K18 since the agonist was not active. Mutant receptors V169 5.30 E, W185 5. 46 A, I249 6.54 A, I253 6.58 A, I253 6.58 E that maintain or increase activity of the studied have relative binding free energies ΔΔG eff that were 1-4.5 kcal mol -1 more positive than K18-WT A 3 R except I249 6.54 A with a ΔΔG eff of ca 10 kcal mol -1 (Table 2, Figure S3 ). Mutants L90 3.32 , L264 7.35 A that increase the potency of the studied antagonist agonist have relative binding free energies ΔΔG eff that were -5.6 and -4.8 kcal mol -1 more negative than K18-WT A 3 R. While more accurate computational methods like FEP/MD 61 are available the calculated ΔΔG eff values using the MM-GBSA allowed us to distinguish the reduction, maintenance and increase of K18 potency against the corresponding mutant A 3 R receptors. 24 c Mean±SD (Å); Protein RMSD is calculated for the C α atoms of the α-helices, for the last 50 ns of the trajectories. Frame 0 is used as reference structure. d Mean±SD (Å); Ligand RMSD is calculated after superposition of each protein-ligand complex to that of frame 0 (reference structure) based on the C α atoms of the protein, for the last 50ns of the trajectories. e N.R.; no response, denotes no agonist activity preventing determination of K18 activity using Schild analysis f Mean absolute error.
Receptor mutations that led to loss or reduction of antagonistic potency. Mutations of residues that are positioned in EL2, TM5, TM6i.e. V169 5.30 For example, the π-π interactions between F168 5.29 and the oxazole ring of the ligand are absent in the mutant F168 5.29 A and this results in the decrease of the hydrogen bond interactions with the critical N250 6.55 and van der Waals interactions with V169 5.30 ( Figure 5 ). The ligand translocates from its starting binding conformations, drifts deeper in the receptor and waters enter the binding area, resulting in an unstable binding mode which is consistent with the ΔΔG eff of +15 kcal mol -1 compared to the WT A 3 R .
In the V169 5.30 A-K18 or M177 5.38 A or L246 6.51 A complexes the ligand has an RMSD lig of ca 4.5 Å and a ΔΔG eff of ca +14 kcal mol -1 or ca 6.7 Å and a ΔΔG eff of ca +14 kcal mol -1 or ca 6.4 Å and a ΔΔG eff of ca +16 kcal mol -1 (SI, Figure S4 , S6, S7). The functional assays suggest that M174 5.35 is also an important residue, since its mutation to alanine led to a reduction of antagonistic potency which is consistent with the RMSD lig of ca 5 Å and a ΔΔG eff of +13 kcal mol -1 ( Figure S5 ). According to the interactions plot from our computational study this residue did not make direct interactions with the WT A 3 R. Although Mutations that maintain antagonistic potency. K18 had a WT-like antagonistic potency for mutant W185 5.46 A, I253 6.58 A A 3 Rs which is in agreement with the ΔΔG eff values of ca +1 and +4.5 kcal mol -1 , respectively ( Table 2) . MD simulations for I253 6.58 A A 3 R-K18 complex showed that, in contrast with WT A 3 R complex, the hydrogen bond interactions with N250 6.55 and the van der Waals interactions with L90 3.32 and with L246 6.51 were maintained. K18 translocated towards TM3 and TM7 with an RMSD of 3.6 Å and as a consequence, the interaction frequency with L264 7.35 was increased while interactions with V169 5.30 were reduced and with V72 2.23 were eliminated. Moreover, a strong hydrogen bond interaction with T87 3.29 appeared as shown in Figure 6 . In the case of K18-I249 6.54 A A 3 R the ligand remained close to the starting binding conformation with RMSD lig value of 2.8 Å and the ΔΔG eff value was ca +10 kcal mol -1 . Significant van der Waals interactions with V169 5.30 , M177 5.38 were reduced but new interactions appeared, i.e. van der Waals with L264, Y265, I268 and water mediated interactions with the backbone amide groups of F168 5.29 (Figure 7) . Mutations that increase antagonistic potency. L264 7.35 A and L90 3.32 A A 3 R mutant showed an increase in antagonistic potency ( Table 2 ). 24 When compared to the K18-WT A 3 R complex, the interactions in L90 3.32 A A 3 R with N250 6.55 , F168 5.29 , L246 6.51 , M177 5.38 , I249 6.54 were maintained. Van der Waals interaction with I249 6.54 and the interaction with F168 5.29 showed a particularly increased frequency, the last due to a strong hydrogen bond interaction between the carbonyl group of K18 and the backbone NH groups of F168 5.29 aided by the reorientation of K18 towards TM6 (Figure 8 ). This reorientation resulted in an RMSD lig value of 3.7 Å. The increase in potency is reflected by the ΔΔG eff value of -6 kcal mol -1 . In the case of L264 7.35 A mutant receptor, K18 maintained interactions with L90 3.32 , F168 5.29 , M177 5.38 , L246 6.51 , N250 6.55 , I249 6.54 stabilizing it inside the binding area. The ligand translocated with an RMSD lig value of ca 3.5 Å, the interactions frequency with L90 3.32 , L246 6.51 and I268 7.39 were increased and a new hydrogen bond interaction with T87 3.29 appeared as shown in Figure 9 . The increase of this complex potency is in agreement with the ΔΔG eff of ca -5 kcal mol -1 ( Table 2 ). Mutations to glutamic acid. It has been suggested that residue (5.30) may be linked to the subtypeselectivity of antagonists and its correct modeling can be used in drug design for the identification of new A 3 R-selective antagonists. Residue I253 6.58 also lies in this area but does not interact directly with K18
according to the MD simulation of the agonists-WT A 3 R complex ( Figure 2B,D) . Seeking to verify the significance of these residues, we mutated V169 5.30 and the remote I253 6.58 to glutamate.
It was expected that K18 with the "up TM5 TM6" conformation having the dichlorophenyl group oriented close to the EL2 should decrease binding affinity and receptor's signaling ( Figure 2D ). However, mutant I253 6.58 E and V169 5.30 E A 3 Rs showed maintenance of potency when bound to antagonist K18. MD simulations showed that binding of K18 can be stable only if the very lipophilic dichlorophenyl group can avoid contacts with glutamate. This is feasible through a 180º rotation of the bond connecting oxazolyl and CO by 180º which results in relocation of the lipophilic dichlorophenyl group away from E 5. 30 and towards the empty space between TM2, TM1 and TM7 giving RMSD lig values of ca 3.5 and 3.6 Å (Figures 10, S7 ). This orientation for K18 inside the WT A 3 R is disfavored by ca 4 kcal mol -1 according to the calculations compared to the orientation with dichlorophenyl group facing TM5, TM6 as mentioned before (Figures 2A-C) . Interactions plot showed that the hydrogen bond interaction between the amino group of the K18 and N250 6.55 , the π-π stacking interaction with phenyl group of F168 5.29 Figure S8 ).
Since in A 1 R and A 2A R there is a glutamic acid in position (5.30), MD simulations were also performed in order to investigate computationally the reason that K18 did not bind to A 1 R and A 2A R. The MD simulations showed that K18 failed to bind with the "up TM5,TM6" conformation due to the repulsions with E169 5.30 but also with "up TM1,TM2" possibly due to the more polar area close to TM1, TM2 in 
Conclusions
The A 3 R is currently an important drug target, 62, 63 and the lack of experimental structure limits the structure-based drug design procedures. We investigate the predictions of a computational model which applies: (a) MD simulations with amber99sb using an homology model of A 3 R in complex with the most likely conformer of K18 inside the binding area, (b) MM-PBSA and MM-GBSA calculations for complexes of K18 and congener molecules to A 3 R, and, (c) complexes of K18 with 14 mutant A 3 Rs. The model was applied to investigate the binding profile of this specific antagonist using previous mutagenic results 23, 24 of several residues of WT A 3 R receptor as experimental probes. 24 In a previous study, 23 acts as a competitive antagonist for IB-MECA. According to the computational model is stabilized inside the A 3 R orthosteric binding area through an "up TM5, TM6" conformer which interacts with few common residues with the agonist. It forms a π-π interaction with F168 5.29 , van der Waals interactions with L90 3.32 , V169 5.30 , L246 6.51 , and hydrogen bond interactions with N250 6.55 . Additionally, K18
interacts directly with M177 5.38 , I249 6.54 the first being an important indirectly interacting residus with M177 5.38 . The computations show that the majority of mutated residues to alanine in direct contact with the antagonist in the WT receptor, should reduce or eliminate potency, i,e. correspondingly V169 5.30 , F168 5.29 , M177 5.38 , L246 6.51 , N250 6.55 according to the computational resuts. This is in agreement with previous experimental results for the mutations V169 5.30 A, M177 5.38 A. 23 In agreement with the previous results, 23 ,24 the computational model shows that the selectivity of K18 or IB-MECA is not only due to direct interactions with the binding area residues, but also due to indirect effects, through residues positioned at the edges of the binding area, like M174 5.35 at 4 Å, or more remote residues. The mutation M174 5. 35 A reduces potency and activity correspondingly for K18 and IB-MECA.
The characterization of the area TM6-EL2-TM5 in A 3 R which includes lipophilic residues is very important for structure-based drug design of selective ligands. Although this area is occupied by the lipophilic part of selective ligands, like the iodo-benzyl group in IB-MECA residues the experimental results shows and the computational model supports 23 that the mutation V169 5.30 E causes, instead of reduction, an increase in IB-MECA and NECA activity and that I253 6.58 is not an important residue of this region. Also that that I253 6.58 is not important and that V169 5.30 E do not reduce but maintaines K18 potency. 24 Our computational model shows that compared to the WT A 3 R the antagonistic potency of K18 was maintained due to the re-orientation of the dichlorophenyl group of the ligand towards TM1, TM2 and the formation of an additional hydrogen bond interaction E169 5.30 in agreement with the previous experimental results. The calculations showed that K18 cannot bind to A 1 R and A 2A R having the E169 5.30 likely due to the presence of more polar residues in these AR subtypes in this region of binding site and the reduced plasticity of this region compared to A 3 R which can contribute to alleviate repulsive interactions through conformational changes.
The previous mutagenesis results are in fair agreement with our computational model. 23, 24 The experimentally determined pA 2 values and the calculated ΔG eff values for K18 displayed very good correlation, with r = -0.82 ( Figure 5 ), while for IB-MECA and NECA the correlation is fair (correspondingly r = -0.69 and r = -0.76). 23 Using the MM-GBSA calculated ΔG eff values it is possible to distinguish the three sets of mutant receptors, i.e. those that reduce or negate K18 potenct at the A 3 R, those that bind stably and maintain potency and those that increase potency compared to WT A 3 R. It is also very interesting that the potency is enhanced by the mutations of L90 3.32 A in the low region or L264 7.35 A in the middle/upper region which are directly interacting residues with K18. The computational model based on the experimental findings 23,24 will be useful for the design of new antagonists which will include substituents above and/or below K18 with adequate orientation towards the low or upper region of the binding area.
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